Israeli biotech Polyrizon is collaborating with NurExone Biologic for intranasal administration of a therapy for spinal cord injuries (SCI).
Under the agreement, Polyrizon — in which Medigus (NASDAQ:MDGS) owns a 37.03% stake — will use its Trap and Target platform to develop formulations, conduct analytical development and produce technical batches of a intranasal delivery system. read more